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Abstract 
Idiopathic membranous nephropathy (IMN) is one of the major causes of adult nephrotic 
syndrome. Associations of phospholipase A2 receptor 1 (PLA2R1) and HLA-DQA1 with IMN 
have been reported in European and Asian populations. However, high-density association 
mapping covering the whole region of PLA2R1 and HLA regions for the association with 
IMN has not been performed yet in the East Asian populations. In the first stage of the study, 
I performed genotyping of 15 SNPs in PLA2R1 and HLA typing of HLA-A, B, C, DRB1, 
DQB1 and DPB1 in patients with 53 Japanese IMN patients and 419 healthy controls. In the 
second stage, I performed replication study with 130 Japanese IMN cases and 392 controls. I 
also analyzed the associations in the combined data set including both first and second sample 
sets. Moreover, interaction analysis of HLA and PLA2R1 was conducted. In the first stage, 
single point analysis on PLA2R1 identified 7 significant SNPs, and in the replication stage, 5 
of which were confirmed. For HLA genes, strong associations were observed with HLA-
DRB1*15:01 and HLA-DQB1*06:02, and both were successfully replicated in the second 
stage. In the interaction analysis, more than additive effect was detected in patients carrying 
both risk alleles of HLA-DRB1-DQB1 and PLA2R1. The present study identified the primary 
associations of HLA and PLA2R1 polymorphisms with IMN in the Japanese population. 
Furthermore, the increased risk of IMN by combination of PLA2R1 and HLA risk alleles 
confirmed the importance of the interaction of these two genes in the development of IMN. 
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Abbreviation 
CKD  Chronic Kidney Disease 
CI  Confidence Interval 
ESRD  End-stage Renal Disease 
GWAS Genome Wide Association Study 
HLA  Human Leukocyte Antigen 
HWE  Hardy-Weinberg equilibrium 
IgG4  Immunoglobulin G4 
IMN  Idiopathic Membranous Nephropathy 
JPT  Japanese population 
LD  Linkage Disequilibrium 
MAF  Minor Allele Frequency 
Mb   Megabase 
MN  Membranous Nephropathy 
OR  Odds Ratio 
Pc  P-value corrected  
PCR  Polymerase Chain Reaction 
PLA2R Phospholipase A2 Receptor 
PLA2R1 Phospholipase A2 Receptor 1 
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RERI  Relative Excess Risk due to Interaction 
RPEs  Rapid Predispositional Effects 
SNPs  Single Nucleotide Polymorphisms 
5’ UTR 5’ Untranslated Region 
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INTRODUCTION 
General Introduction of Nephrotic Syndrome 
Chronic kidney disease (CKD) describes a progressive loss of renal function over a 
period of months or years. According to the survey of Japanese Society of Nephrology, more 
than 13 million people have CKD, and treatment is preferable in 40% of them. Furthermore, 
end-stage renal disease (ESRD) is increasing together with aging society. In Japan, More than 
three hundred thousand people receive dialysis in 2011 [1]. CKD including ESRD has multiple 
complications such as hypertension, cardiovascular disease, anemia and mineral-bone disorder. 
It worsens quality of life and increases financial burden. 
In many CKD cases, proteinuria is present. Nephrotic syndrome is an advanced 
type of kidney diseases in terms of massive proteinuria. Nephrotic syndrome accompanies 
hypoalbuminemia, edema, and occasionally pleural effusion, ascites, and thrombotic tendency. 
Treatment duration generally is as long as several years in this disease. Thus, comprehension 
of nephrotic syndrome is an urgent issue in a nephrology field. 
Idiopathic Membranous Nephropathy 
Membranous nephropathy (MN) is one of the most common causes of adult 
nephrotic syndrome. MN is a rare disease with the incidence rate of approximately 1 case in 
100,000 persons per year [2]. Eighty percent of MN patients are classified as “idiopathic” 
while the remaining twenty percent are known as “secondary” for being associated with other 
medical conditions including systemic lupus erythematous (SLE), chronic infections 
including hepatitis B, graft vs host disease, drugs and toxins including penicillamine and 
mecury [3-5]. Idiopathic membranous nephropathy (IMN) is characterized by subepithelial 
immune complex deposition of glomerular basement membrane, which is regarded as the 
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landmark of the diagnosis of MN. 
The immune deposition of IgG and complement cause the functional impairment of 
glomerular epithelial wall which results in proteinuria [6]. A demographic study published in 
2012 reported the mean age of IMN patients in Japan was 62.2 (2-88) years old [7], with male 
to female ratio of 1.3, which was lower than that of 2.0 in North Americans, Australians and 
Asians [8, 9]. IMN is a chronic disease that is known for its clinical course of spontaneous 
remission and relapses. It was reported that 20-40% of IMN patients developed to ESRD after 
10 to 15 years in Caucasian population [10-12]. In contrast, IMN is considered to run a more 
benign clinical course and good prognosis in Japanese than in European population [10, 12, 
13]. Better prognosis was observed in Japanese IMN patients than in European patients 
despite more advanced histological findings [14]. 
In Japan, Shiiki et al reported that the overall renal survival rates were 95.8%, 
90.3%, 81.1%, and 60.5% at 5, 10, 15, and 20 years after diagnosis, respectively. Male gender, 
old age (greater than or equal to 60 years), high serum creatinine concentration (greater than 
or equal to 1.5 mg/dL), and the development of tubulointerstitial lesions (greater than or equal 
to 20% of the biopsy sample area) were significant predictors of progression to ESRD [15]. 
What determines the difference of outcome among populations has been unclear. Therefore, it 
is worthwhile to investigate Human Leukocyte Antigen (HLA) involvement in IMN. 
PLA2R1 is a 185-kD transmembrane glycoprotein that is a member of the mannose 
receptor family [16, 17]. Anti-PLA2R (M-type phospholipase A2 receptor) antibodies were 
detected in 70% of patients with IMN, but not secondary membranous nephropathy indicating 
PLA2R as a major target antigen in this disease and establishing IMN as an autoimmune 
disease [8]. PLA2R antibodies are not detected in healthy individuals or patients with other 
causes of nephrotic syndrome [18, 19]. According to several studies, anti-PLA2R1 antibodies 
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show correlation with disease activity; disappearing during a spontaneous or treatment-
inducted remission and reappearing during relapse [20-22]. PLA2R is reported to being 
predominantly expressed in human kidney tissues [23], and also found to be present in the 
lungs and on leukocytes [24, 25]. Despite being expressed in other body tissues, the disease is 
limited only to kidneys and the exact role of PLA2R1 in the pathogenesis of IMN is still 
unknown. 
Recent genome-wide association study (GWAS) including independent cohorts of 
three European populations has identified PLA2R1 on chromosome 2 and HLA-DQA1 on 
chromosome 6 to be susceptible genes to IMN [26]. Interestingly, Stanescu et al. also 
reported a strong genetic interaction of risk alleles at both HLA (rs2187668) and PLA2R1 
(rs4664308), although relatively modest risk of IMN was identified at each locus. It is 
assumed that genetic variation in immune response gene (HLA) and podocyte gene (PLA2R1) 
may lead to the production of autoantibodies resulting in development of IMN [27]. However, 
this assumption has not been proved experimentally yet. In a subsequent study, Coenen et al. 
performed sequencing of PLA2R1 exons in IMN patients in order to study whether rare 
variants are responsible for the development of IMN, but the result did not prove the 
hypothesis [28]. PLA2R1 association with IMN was also reported by case-control candidate 
gene studies in European, African Americans and Asians including Chinese, Taiwanese and 
Koreans [29-32]. 
IMN association with certain HLA class II genes has long been known [33-35]. 
Strong association of HLA-B8DR3 with IMN was reported in European Caucasoids [36, 37]. 
In recent years, association of a single nucleotide polymorphism (SNP) in HLA-DQA1 
(rs2187668) with IMN has also been reported [26, 32, 38]. 
Human leucocyte antigen (HLA) genes are known as the most polymorphic genes in 
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human genome stretching around 6 megabase pairs (Mb) on chromosome 6 [39]. HLA super-
locus encodes six classical genes, which have important roles in the regulation of the immune 
system. HLA locus is considered to be one of the most gene dense and complex genes, and 
reported to be associated with more than 100 different diseases, including autoimmune 
diseases and some other complex diseases [40]. 
SNPs have been widely used as markers in genetic studies for detecting disease 
susceptibility genes by using standard single-locus test. Nowadays, the interest has been 
moving to the detection of effects by gene-gene interactions (epistasis) and gene-environment 
interactions which will be helpful in understanding the biological pathways of diseases [41]. 
Bateson in 1901 used the term epistasis to describe the masking effect of one gene upon 
another gene. In 1918, Fisher expanded the term to include any statistical deviations from 
additivity of the two loci. 
In Japan, IMN was reported to account for 77.9% of total membranous nephropathy 
patients while membranous nephropathy was present in 36.8% of primary nephrotic 
syndrome patients [7]. Limited number of genetic studies of IMN has been reported so far. 
Despite previous studies have reported the effect of single locus and the genetic interaction of 
SNPs in PLA2R1 and HLA-DQA1 regions, no study to date, has performed the high-density 
association mapping of both PLA2R1 and HLA regions for identifying the primary 
polymorphisms and it is still not known the interaction effect of PLA2R1 risk variants and 
classical HLA alleles. Thus, the objective of this study is to fill a gap in the understanding of 
genetics of IMN by high-resolution study of PLA2R1 and HLA regions. Besides the single 
point associations, interaction analysis between HLA and PLA2R1 risk alleles was performed. 
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MATERIALS AND METHODS 
Human subjects and sample collection 
This study included a total of 989 subjects comprised of healthy controls and cases 
with (biopsy-proven) idiopathic membranous nephropathy. The study was approved by the 
Ethical Committees at The Faculty of Medicine at The University of Tokyo, BioBank Japan 
and Pharma SNP Consortium (Tokyo, Japan) 
(http://www.jpma.or.jp/information/research/psc/e02psc/about.html). Written informed 
consent was obtained from each participant before sample collection. In the first set of study, 
I recruited 53 biopsy-proven IMN patients and 419 healthy controls residing around Tokyo 
area. IMN samples were collected by the department of Hemodialysis and Apheresis of the 
University of Tokyo Hospital, and control samples were collected by the Department of 
Human Genetics of the University of Tokyo. Diagnosis of the IMN patients was established 
by renal biopsy together with other routine clinical procedures. Patients with any evidence of 
secondary memebranous nephropathy were excluded from the study. Either needle renal 
biopsy or open renal biopsy was performed. Control samples were collected from volunteer 
healthy individuals. In the second set of study, 130 IMN cases collected by BioBank Japan 
and 392 healthy controls from the Department of Hemodialysis and Apheresis of The 
University Tokyo Hospital and Pharma SNP Consortium (Tokyo, Japan) were analyzed for 
replication purposes. Among control samples used in replication study, 200 samples were 
collected from healthy individuals visiting the health centers for routine medical check-up, 
and 192 samples were part of the samples from Pharma SNP Consortium. Control samples 
were not collected from healthy individuals who were not being diagnosed with any kidney 
diseases. Both the discovery and replication studies included the Japanese individuals. 
 
! 10 
PART 1: Fine mapping of PLA2R1 gene 
Study overflow of fine mapping of PLA2R1 was shown in Figure 1. 
Tag Single Nucleotide Polymorphism (SNP) Selection 
SNP genotype information of PLA2R1 was downloaded from the HapMap JPT 
population database (http://hapmap.ncbi. nlm.nih.gov/). HapMap data was analyzed using 
Haploview software (ver 4.1) and I selected Tag SNPs by using Tagger algorithm 
implemented in Haploview [42]. I selected SNPs by applying the following selection criteria: 
(i) minor allele frequency (MAF) threshold of > 0.10 in the HapMap JPT population, (ii) r2 
threshold of greater than or equal to 0.8 (Figure 2). Finally, I selected a total of twelve tag 
SNPs meeting the criteria together with additional three reported SNPs (rs35771982, 
rs4665143 and rs3749119) from previous literatures [28], to validate their association with 
idiopathic membranous nephropathy in the Japanese population. The previously reported 
SNP, rs3828323, in European and Korean studies [28, 29], was known to be in LD with the 
tag SNP rs1511223 in 3’ UTR region, and thus excluded from this study. 
SNP Genotyping 
The genomic DNA was extracted from the peripheral blood at each institution 
following the standard protocol. The concentration of genomic DNA was determined using 
spectrophotometer (NanoDrop ND-1000, NanoDrop Technologies). I performed genotyping 
of the total 15 SNPs using discovery sample set of 472 individuals by using the TaqMan SNP 
Genotyping Assay (ABI: Applied Biosystems Inc. Foster City, CA, USA) to determine the 
genotypes according to the manufacturer’s protocol. For TaqMan Genotyping Assay, 10 ng of 
genomic DNA was used per reaction well. The mixture for every reaction was prepared with 
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2.5 l of KAPA PROBE FAST qPCR Master Mix (Kapa Biosystems, Woburn, MA), and 
0.125 l of TaqMan SNP Genotyping Assay primer/probe (40x) from Applied Biosystem 
and 1.375 l of Milli Q water. Then, 4 l of reaction mixture was added to the 1 l of 
DNA template. The polymerase chain reaction (PCR) was performed using Light cycler 480II 
(Roche, Germany) with cycling parameters of 95 °C for 3 minutes, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute. 
I also performed TaqMan SNP genotyping of significant variants (rs1511223, 
rs35771982, rs10196882, rs877635, rs2715928, rs16844715 and rs3749119) in the replication 
study including 522 IMN cases and healthy controls. 
Statistical analysis 
Single locus association analysis 
To compare the allele and genotype frequencies between case and control groups, 
chi-square test or Fisher exact test was applied as appropriate. Departure from Hardy-
Weinberg equilibrium (HWE) was tested in all SNPs by a chi-squared goodness-of-fit test. 
Association analyses of all SNPs in PLA2R1 gene were performed by using PLINK software 
(http://pngu.mgh.harvard.edu/purcell/plink/) [43]. 
Haplotype association analysis  
Haplotype association test was conducted using the combined data set including 
183 IMN cases and 811 healthy controls. Out of 13 SNPs selected in this study, 5 SNPs with 
significant associations in all data sets were included in haplotype analysis. HaploView 
software [44] and the sliding window analysis implemented in PLINK were used to display 
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the linkage disequilibrium structure of PLA2R1 SNPs in JPT HapMap samples and to perform 
a haplotype analysis of PLA2R1 gene. 
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PART 2: Associations of HLA genes with IMN 
Study overflow of HLA association with IMN was shown in Figure 3. 
HLA genotyping 
Genotyping for six HLA genes (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1) was 
performed in 53 Japanese idiopathic membranous nephropathy patients by the polymerase 
chain reaction (PCR)-Luminex typing method using the WAKFlow HLA typing kit 
(Wakunaga, Hirohsima, Japan) (Figure 4). Briefly, target DNA was amplified by PCR 
(polymerase chain reaction) with biotinylated primers specifically designed for each HLA 
locus. The PCR product was then denatured and hybridized to complementary 
oligonucleotide probes immobilized on fluorescent coded microsphere beads. In the 
meanwhile, biotinylated PCR products were labeled with phycoerythrin-conjugated 
streptavidin and finally examined with Luminex 100. Genotype determination and data 
analysis were performed automatically, using the WAKFlow typing software. For healthy 
control samples, I utilized HLA data published previously [45]. HLA typing of significant 
HLA regions, HLA-DRB1 and DQB1, was performed for the second set of samples for the 
replication study. 
Statistical analysis 
HLA single locus association analysis 
To compare HLA allele frequency and carrier frequency between IMN patients and 
controls, I used Chi-square test when the sample number was 10 or more than 10 and used 
Fisher’s exact test when the sample number was less than 10. I also conducted Relative 
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predispositional effects (RPEs) tests to identify the associations sequentially according to 
their strengths [46]. When any of the obtained value was zero, the odds ratio was calculated 
using Woolf’s correction. The odds ratio (OR) with 95% CI was also calculated. Bonferroni 
correction for multiple testing was applied and corrected P values (Pc) were calculated by 
multiplying the P values by the number of alleles tested for each locus. 
HLA haplotype association analysis  
I also performed HLA haplotype association analysis applying Arlequin algorithm 
[47]. Two-locus haplotypes (DRB1-DQB1) were calculated between IMN cases and controls 
by maximum likelihood methods. 
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PART 3: Genetic interaction between PLA2R1 and HLA risk alleles 
Interaction analysis was performed using combined data set including a total of 981 
samples (182 IMN cases and 799 healthy controls). Samples with failed genotyping in either 
PLA2R1 or HLA region were excluded from analysis. Five PLA2R1 SNPs (rs1511223, 
rs35771982, rs2715928, rs16844715 and rs3749119) significantly associated in both first and 
second stages, and significantly associated HLA haplotype, HLA-DRB1*15:01—DQB1*06:02 
were included. Individuals carrying risk alleles of PLA2R1 and HLA were compared with 
those with non-risk alleles using chi-square test or Fisher’s exact test. Additive interactions 
were also tested using RERI, Relative Excess Risk due to Interaction [48]. RERI is equal to 0 
means there is no biological interaction or exactly additivity and RERI greater than 0 means 
positive interaction or more than additivity [49, 50]. 
 
 
 
 
 
 
 
 
 
! 16 
RESULTS 
PART 1: Fine mapping of PLA2R1 gene 
Association analysis of PLA2R1 SNPs in the first set of IMN patients and controls 
Fine mapping of PLA2R1 SNPs was performed in the first stage of the study 
including 53 IMN patients and 419 healthy controls. Of the 15 SNPs genotyped, two SNPs 
failed in genotyping and were therefore excluded from the study. Significant deviations from 
Hardy-Weinberg equilibrium (P<0.05) were not observed for any of the 13 SNPs included in 
the study. Of 13 SNPs included in the association analysis, I found 9 SNPs significantly 
associated with IMN (P<0.05) (Table 1). When I corrected for the multiple testing, 7 SNPs 
survived to be significant (Table 2). 
Replication in the second data set and combined analysis 
Seven significant SNPs in the first set were attempted to replicate in a total of 130 IMN 
patients and 392 healthy controls. Five SNPs (rs1511223: P=8.88×10-3; OR=1.57, 
rs35771982: P=1.52×10-8; OR=2.57, rs2715928: P=2.43×10-8; OR=2.36, rs16844715: 
P=7.96×10-8; OR=2.23, and rs3749119: P=1.21×10-8; OR=2.61)!were successfully replicated, 
while rs10196882 and rs877635 did not reach significant level in the second set.!
When the association analysis was conducted in the combined data sets, 
rs35771982 and rs3749119 (which are in high linkage disequilibrium with each other) 
exhibited the strongest associations (P=3.09×10-15, OR=2.93 and P=2.16×10-15, OR=3.02, 
respectively) (Table 2). Two intronic SNPs, rs2715928 (P=2.10×10-11, OR=2.30) and 
rs16844715 (P=3.77×10-14, OR=2.51), also showed significant associations with IMN. 
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Haplotype association analysis  
As part of the association analysis, I also performed haplotype association tests in 
order to determine whether haplotypes from combination of common variants increased the 
risk of IMN. I performed haplotype analysis including SNPs, which were consistently 
significant in all data sets, using the HaploView software and PLINK sliding window 
analysis. Analysis of LD pattern showed high LD (r2=0.81) between rs35771982, missense 
SNP located in exon 5, and rs3749119 located in 5’ untranslated region (5’ UTR) of PLA2R1 
and more significant SNP (rs35771982) was included in the haplotype analysis. Haplotypes 
with low frequency (<1%) in either cases or controls were excluded. Compared to the risk and 
strength of association by single variant analysis, sliding window haplotype analysis in 
PLINK including two, three and four markers did not exhibit stronger association nor higher 
risk with IMN (Table 3). 
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PART 2: Associations of HLA genes with IMN 
Allelic association 
Association analysis of HLA genes in the first set of IMN patients and controls 
In the discovery stage, HLA-A, -B, -C, -DRB1, -DQB1 and –DPB1 genotypes were 
determined in a total of 53 IMN patients and 419 healthy controls. Regarding HLA class I 
genes, HLA-A*33:03 showed a marginal association (P=0.03, OR=0.4) with IMN (Table 4). 
Tendency of negative association was observed in HLA-B*07:02 and HLA-B*4403 with IMN 
while positive association was found with HLA-B*35:01 (Table 5).  HLA-C*0704 exhibited a 
high odds ratio for IMN (P=5.79E-03, OR=5.89) although it remained not significant when 
the p-value was corrected for the number of alleles tested. Little evidence of negative 
association was observed in two other HLA-C alleles, HLA-C*01:02 and HLA-C*14:03 with 
IMN (Table 6). No alleles mentioned above remained significant after correction for multiple 
comparisons. 
Regarding HLA class II genes, HLA-DRB1*15:01 was the most strongly associated 
allele (P=7.72×10-5, OR=2.85), which remained to be significant when P-value was corrected 
for the number of alleles tested (Table 7). Negative association was also observed in HLA-
DRB1*01:01, HLA-DRB1*04:05 and HLA-DRB1*13:02. Among four HLA-DQB1 alleles that 
showed significant associations with IMN, HLA-DQB1*06:02 (P=5.12×10-4, OR=2.60) only 
survived to be significant after correction for multiple comparisons (Table 8). No association 
was observed between HLA-DPB1 alleles and IMN (Table 9). 
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Replication in the second sample set and combined set 
The replication study of two HLA class II genes, HLA-DRB1 and HLA-DQB1, was 
performed in an independent set of 130 IMN patients and 392 healthy controls. A significant 
positive association was also observed for HLA-DRB1*15:01 and HLA-DQB1*06:02 with 
IMN in the replication stage with P=1.71×10-9, OR=3.36 and P=5.14×10-10, OR=3.56, 
respectively (Tables 10 and 11). Except for HLA-DRB1*13:02 and HLA-DQB1*06:04 which 
showed marginal association with IMN, none of the significant HLA-DRB1 and HLA-DQB1 
alleles in first set was found to have P-value<0.05. 
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Relative Predispositional Effects (RPEs) with IMN 
In the combined data analysis, both HLA-DRB1*15:01 and HLA-DQB1*06:02 
emerged with stronger evidence of associations with IMN holding P=3.94×10-13, OR=3.09 
and P=8.90×10-13, OR=3.10, respectively (Tables 10 and 11). I also performed RPEs testing to 
further explore the associations between HLA-DRB1 and HLA-DQB1 alleles with IMN in the 
combined analysis. In RPEs testing, sequential elimination of carriers of each allele with the 
most significant association was performed to identify the associations sequentially according 
to their strength. In the analysis of HLA-DRB1, the most significant association was between 
DRB1*15:01 and IMN (P=3.94×10-13, OR=3.09) in the combined analysis. The analysis was 
conducted again after elimination of DRB1*15:01 carriers. The next most significant positive 
association was observed between DRB1*14:54 and IMN (P=1.00×10-4, OR=2.05).  When the 
third turn of analysis was performed after elimination of both DRB1*15:01 and DRB1*14:54 
carriers, the next most significant association was found at DRB1*11:01 (P=8.54×10-4, 
OR=2.15). Further rounds of association analysis after eliminating the carriers of 
DRB1*15:01, DRB1*14:54 and DRB1*11:01 did not show any DRB1 alleles which survived 
to remain significant after multiple correction (Table 10).  
Regarding to HLA-DQB1 analysis, the most significant association was found 
between DQB1*06:02 and IMN (P=8.90×10-13, OR=3.1). Analysis after elimination of 
DQB1*06:02 carrier showed the next most significant association to be DQB1*05:02 with 
IMN (P=9.86×10-5, OR=2.34). The next most significant association after elimination of both 
DQB1*06:02 and DQB1*05:02 carriers was found to be DQB1*03:01 with IMN (P=3.11×10-
3, OR=1.48). After elimination of carriers of all DQB1*06:02, DQB1*05:02 and 
DQB1*03:01, the next most significant association was observed to be DQB1*05:03 with 
IMN (P=2.96×10-3, OR=1.68). Further analysis after sequential elimination of all 
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DQB1*06:02, DQB1*05:02, DQB1*03:01 and DQB1*05:03 did not reveal any DQB1 alleles 
that passed significant level after multiple correction (Table 11). 
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DRB1*15:01-DQB1*06:02 haplotype distribution 
Two-locus haplotype frequencies were calculated in the combined data set (182 
IMN cases and 799 controls) by Arlequin software. Haplotypes with frequencies less than 1% 
in both cases and controls were excluded from the study and major haplotypes are shown in 
Table 7. In control group, the most common haplotype was found to be DRB1*09:01-
DQB1*03:03 present in 222 of 799 controls (27.8%) and the second most common haplotype 
was DRB1*04:05-DQB1*04:01 observed in 194 of 799 controls (24.3%). Among IMN 
patients, DRB1*15:01-DQB1*06:02 present in 69 of 182 IMN cases (37.9%) was observed to 
be the most common haplotype and DRB1*15:02-DQB1*06:01 found in 42 of 182 cases 
(23.1%) was found to be the second most common haplotype. 
 
DRB1*15:01-DQB1*06:02 Haplotype association 
The results of HLA-DRB1-DQB1 haplotype association analysis were shown in 
Table 12. The most susceptible haplotype observed in this study was DRB1*15:01-
DQB1*06:02 haplotype (P=1.89×10-12, OR=3.07). The other susceptible haplotypes were 
DRB1*14:54-DQB1*05:02 haplotype (P=2.67×10-3, OR=3.1), DRB1*11:01-DQB1*03:01 
haplotype (P=3.21×10-3, OR=2.34) and DRB1*04:01-DQB1*03:01 haplotype (P=5.16×10-3, 
OR=2.71).  The most protective haplotype was observed to be DRB1*13:02-DQB1*06:04 
haplotype (P=6.10×10-3, OR=0.44). 
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PART 3: Genetic interaction between HLA and PLA2R1 risk alleles 
In the single point analysis of the fine mapping study of PLA2R1 gene, I found 5 
significant SNPs (rs1511223, rs35771982, rs2715928, rs16844715, and rs3749119) in the 
first stage were successfully replicated in the second stage. Regarding to HLA study of IMN, 
HLA-DRB1*15:01 and DQB1*06:02 were significant in both the first and the second stages 
of the study. Sixty-nine (37.9%) of IMN patients were found to carry HLA-DRB1*15:01-
DQB1*06:02 haplotype (P=1.89×10-12, OR=3.07). I, therefore, analyzed the total of 182 IMN 
cases and 799 healthy controls (both HLA-matched and non-HLA-matched controls with 
HLA-DRB1*15:01-DQB1*06:02) to investigate the interactions between HLA-DRB1*15:01-
DQB1*06:02 haplotype and PLA2R1 risk alleles.  
Interaction analysis exhibited positive interaction or more than additive effects with 
IMN (Table 13). I observed that the evidence for the interaction was strongest between HLA-
DRB1*15:01 - HLA-DQB1*06:02 and the intronic SNP rs2715928 (OR=17.53, P=4.26×10-26, 
and RERI=13.72). It was found that 18.6% of patients carried both rs2715928 and HLA-
DRB1*15:01-DQB1*06:02 while 1.9% of controls possessed them. 
In addition, positive interaction was also observed between HLA-DRB1*15:01 - 
HLA-DQB1*06:02 and the missense SNP rs35771982 (OR= 15.91, P=2.76×10-29, and 
RERI=10.88) that is in strong LD with 5’UTR SNP rs3749119, and intronic SNP rs16844715 
(OR=15.91, P=2.30×10-26, and RERI=11.34) for IMN. The data showed that 23.2% of IMN 
cases and 3.4% of controls carried both rs35771982 and HLA-DRB1*15:01 - HLA-
DQB1*06:02, and rs3749119 and HLA-DRB1*15:01 - HLA-DQB1*06:02 risk allele 
combinations. 
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These results suggest that risk allele of PLA2R1 risk variants causes an increased 
risk of IMN in individuals carrying HLA-DRB1*15:01-DQB1*06:02 haplotype. 
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DISCUSSION 
General discussion 
The genetic association of PLA2R1 and HLA-DQA1 risk alleles with IMN in the 
European populations was reported by a GWAS study that included three independent 
genome-wide association studies in three populations [26]. Coenen et al. subsequently 
investigated the effect of rare variants on IMN by sequencing PLA2R1 exons in European 
ancestry patients, and the results did not prove the positive association of rare variants with 
IMN [28]. So far, associations of PLA2R1 with IMN have not been investigated in the 
Japanese population. In this study, I aimed to identify the primary risk SNPs of PLA2R1, and 
HLA risk alleles and their haplotypes, the interaction between the risk alleles of PLA2R1 and 
HLA genes on the development of IMN through high-resolution association study.  
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PART 1: Fine mapping of PLA2R1 gene 
This study identified significant association of PLA2R1 with IMN in Japanese. I 
found 7 SNPs within PLA2R1 gene confirmed to be significantly associated with IMN, 
including a non-synonymous SNP (H [His]  D [Asp]) and a 5’ UTR SNPs reported in 
previous studies [28-30, 32], and additional 5 SNPs. In the Japanese population, rs35771982 
of PLA2R1 was the most strongly associated with IMN. In agreement with the reports of 
Coenen et al. and Liu et al [28, 30]. I found that G allele of non-synonymous SNP, 
rs35771982, which is in strong LD with 5’ UTR SNP, rs3749119 had significantly increased 
the risk of developing IMN. Contrary to our finding and to those by Coenen et al. and Liu et 
al., Lv et al. and Kim et al. reported that C allele of rs35771982 elevated the risk of IMN [29, 
31]. Consistent with our result, Coenen et al. also reported that C allele of rs3749119 raised 
the risk of IMN. This finding provided the first independent replication of positive association 
of rs3749119 with IMN susceptibility. Additionally, I observed a significant association with 
A allele of rs1511223, located in 3’ UTR with IMN, which is in agreement with the result 
reported by Saeed et al [32]. The SNP (rs1511223) is located in high LD with rs3828323 that 
was reported to be associated with IMN in European and Korean populations [28, 29]. 
Moreover, the current study identified the new significant associations of two 
intronic SNPs, both located in the first intron of PLA2R1. Our results also suggest that rare 
haplotypes from combination of common variants within PLA2R1 region may not explain the 
rare occurrence of IMN in general population. 
It was reported that the prevalence of idiopathic membranous nephropathy was 
lower in Japanese than in the European and other Asian populations [51]. The results of fine 
mapping study show a stronger association of IMN with PLA2R1 (Table 2) than HLA, which 
was in agreement with the Chinese study [31] and opposite to the findings from European 
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GWAS study [26]. Stanescu et al. reported the stronger association of IMN with HLA than 
PLA2R1. These findings suggest that the risk of idiopathic membranous nephropathy is higher 
with PLA2R1 than with HLA, supporting the finding reported by Beck and Colleagues [8]. 
However, the process of antibody formation and the pathologic role of PLA2R1 in IMN are 
still not clearly understood. It is evident from the data that risk alleles of PLA2R1 are common 
in general population, and yet idiopathic membranous nephropathy is still rare disease, 
suggesting the contributions of other risk factors (genetic and environmental factors) to the 
development of IMN. 
 
 
 
 
 
 
 
 
 
 
 
 
! 28 
PART 2: Associations of HLA genes with IMN 
With respect to HLA association with IMN, recent studies have reported the strong 
association of HLA-DQA1 SNP rs2187668 with IMN in European and Chinese populations 
[26, 31]. It has been reported that rs2187668 is a tag SNP for HLA-DRB1*03:01 in northern 
European populations, and the haplotype including DRB1*03:01 was associated with 
membranous nephropathy [12, 52, 53]. 
This part of the study aimed to identify the most important HLA alleles for IMN 
through HLA typing approach. This study identified the strong positive associations of HLA-
DRB1*15:01 and DQB1*06:02 with IMN in Japanese population that were replicated in the 
second sample set and combined dataset. Similar association with IMN was not found in other 
populations. However, these individual or haplotype associations with different immune 
disorders have been reported in different populations [54-57]. 
In a French population, increased frequency HLA-DR3 and decreased frequency of 
HLA-DMA*01:02 was associated with IMN [33]. Taken together, the discrepancy of HLA 
associations with IMN in different populations may explain the population difference in the 
genetic contribution to the development of IMN and difference of disease severity of IMN as 
a phenotype. In British IMN patients, Vaughan et al. reported the associations of HLA-
DRB1*03:01, HLA-DQA1*05:01 and HLA-DQB1*02:01 with IMN [35]. Both DRB1*03:01 
and DQB1*02:01 alleles are less common in the Japanese population. Not many studies 
regarding the HLA associations of IMN have been reported worldwide yet. 
IgG4 antibodies were detected in 26 of 37 patients with IMN [8]. IgG4 co-localized 
with PLA2R in the immune complex deposition on the glomerular basement membrane in 
patients with IMN, but not in those with secondary MN. Significantly higher frequency of 
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HLA-DRB1*15 was reported in primary sclerosing cholangitis patients with increased levels 
of IgG4 inserum [58]. Elevated serum concentrations of IgG4 are found in 60 to 70 percent of 
patients with IgG4-related disease. Hence, HLA may be associated with IgG4-related IMN. 
 With respect to HLA class I, no association of HLA class I alleles with IMN has 
been reported to date. In our analysis of the discovery set including 472 samples of IMN cases 
and healthy controls, I also observed the weak association of HLA-B*07:02 with IMN before 
correction appearing in 1 of 53 IMN patients (1.9%) and 53 of 419 healthy individuals 
(12.6%). Additionally, our results showed the weak association of HLA-C*01:02 with IMN 
before correction although the association ceased to be significant when I corrected P-value 
for multiple correction. Our study also showed the potential risk of HLA-C*07:04 with 
Japanese IMN patients. HLA-C*07:04 was reported to increase relative risk for 
carbamazepine-induced cutaneous adverse reactions in Japanese [59]. The shared HLA allelic 
associations might have a pathological role because some kidney diseases such as vasculitis 
also develop skin symptoms.  
HLA-DRB1-DQB1haplotype analysis identified a strong positive association 
between HLA-DRB1*15:01-DQB-06:02 haplotype and IMN in Japanese population. It is 
known that 12% of general Japanese population carries the haplotype. DRB1*15:01-
DQB1*06:02 haplotype was also found to be associated with Narcolepsy [60, 61] and 
Essential Hypersomnia [62] in Japanese population. Although, this study also identified 
potential susceptible and protective haplotypes to be associated with IMN, DRB1*15:01-
DQB1*06:02 haplotype exhibited the strongest association with IMN in Japanese. 
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PART 3: Genetic interaction between PLA2R1 and HLA risk alleles 
European GWAS study and a number of recent studies have reported the elevated 
risk of susceptibility to IMN in the patients carrying both HLA SNP (rs2187668 which is 
known as a tag SNP for HLA-DRB1*03:01) and PLA2R1 variants [26, 31, 32]; however, no 
study has reported the interaction between classic HLA alleles or HLA haplotypes and 
PLA2R1 risk variants with IMN until today. 
Therefore, the present study was designed to examine the risk of combined effect of 
HLA and PLA2R1 in the Japanese IMN patients. I carried out the case-control association 
study including 182 IMN patients and 799 healthy control individuals to investigate the 
interaction effect between PLA2R1 and HLA risk alleles which were significant in both 
discovery and replication stages in this study. HLA-DRB1*15:01 and DQB1*06:02 are in 
tight LD in Japanese population and known to be in haplotype showing significant 
associations in both single point and haplotype analyses. 
Our results from the interaction analysis confirmed the increased risk of IMN by 
PLA2R1 and HLA together, and additionally proved that IMN patients with risk haplotype 
HLA-DRB1*15:01-DQB*06:02 and risk alleles of PLA2R1 conferred the elevated risk 
(highest OR = 17.53) for the development of IMN. The present study identified positive 
interaction or more than additive effects on the risk of IMN among the individuals with risk 
alleles of five PLA2R1 SNPs (rs1511223, rs35771982, rs2715928, rs16844715 and 
rs3749119) and HLA-DRB1*15:01-DQB1*06:02. Little is known about the mechanism 
involved in the interaction between HLA and PLA2R1, and disease development. It may be 
possible that PLA2R1 risk variants may introduce a unique conformation in the protein, 
which lead to preferential antigenic peptide recognition by the predisposing HLA haplotype, 
HLA-DRB1*15:01-DQB1*06:02, and result in the production of autoantibodies. These 
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findings of the increased risk of IMN by interaction between HLA haplotypes and PLA2R1 
SNPs further supports the concept that genetic interaction between HLA and PLA2R1 may 
interfere with the immune regulation resulting in predisposition to the development of 
idiopathic membranous nephropathy, and provide the clues to the better understanding of 
pathogenesis of IMN. To date, out study is the first to report the increased risk of interaction 
effect between PLA2R1 risk variants and HLA risk haplotype in IMN. 
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CONCLUSIONS 
The present study was aimed to investigate the genetic risk factors of IMN by high-
density mapping approach. This study provides the evidences of PLA2R1 and HLA 
associations with IMN in Japanese population. In fine mapping study of PLA2R1, I observed 
7 SNPs to be strongly associated with IMN. In the HLA association study, I identified 2 
highly significant HLA alleles together with several potential alleles. The most interesting 
finding to emerge from the present study is that the risk of IMN is highly increased by the 
combination of PLA2R2 and HLA. In contrast to European GWAS study, this study identified 
different HLA risk alleles and interaction between HLA and PLA2R1 suggesting the racial 
difference in the genetic contribution of disease susceptibility and severity of IMN. The 
current data also highlight the importance of interaction effect of PLA2R1 and HLA in the 
development of IMN.  Furthermore, this is the first study to investigate the positive 
interaction or more than additive effects between HLA risk haplotype and PLA2R1 risk 
variants. The key strengths of this study are the identifications of classic HLA alleles by 
advanced HLA typing technology and the interactions between HLA-DRB1*15:01-
HQB1*06:02 haplotype and PLA2R1 risk variants. The findings in this study provide a new 
understanding to the development of IMN. Due to the little understanding of the pathological 
mechanism of the interaction of PLA2R1 and HLA in IMN, further studies (genetic and 
functional) are needed for the better understanding of IMN development. 
This study has several limitations. Firstly, sample size was relatively small for 
genetic association study. However, given the strength of the associations of both PLA2R1 
and HLA alleles, this study shows that the relatively small size of cases is sufficient enough to 
identify the significant alleles in rare diseases like idiopathic membranous nephropathy. 
Secondly, the comparison among pathological findings and clinical courses and genotyping 
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data was impossible because all the samples were anonymised. Impact of genetic risk alleles 
on responsiveness to treatment as well as histological and clinical severity may be clinically 
useful. 
In summary, this three-staged study of 182 IMN cases and 811 healthy controls 
identified the genetic risk alleles of PLA2R1 and HLA in Japanese and confirmed the 
increased risk conferred by the combination of PLA2R1 and HLA risk alleles. 
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TABLES 
 
Table 1. Association analysis of PLA2R1 SNPs with IMN in the first sample set
No % No %
rs1511223 3' UTR A 88 83.0 569 68.6 2.24(1.32-3.8) 2.17E-03
C 18 17.0 261 31.4
rs2715931 intronic A 18 17.0 94 11.2 1.61(0.93-2.8) 0.09
C 88 83.0 742 88.8
rs35771982 missense G 87 82.1 469 56.1 3.58(2.14-6) 3.01E-07
C 19 17.9 367 43.9
rs10929964 intronic T 27 26.0 201 24.3 1.09(0.69-1.74) 0.71
A 77 74.0 627 75.7
rs2203053 intronic G 55 52.9 345 41.5 1.58(1.05-2.39) 0.03
A 49 47.1 487 58.5
rs10196882 intronic T 30 28.8 126 15.3 2.25(1.42-3.58) 4.72E-04
C 74 71.2 700 84.7
rs6751162 intronic A 24 23.1 181 22 1.07(0.66-1.73) 0.80
C 80 76.9 643 78
rs16844706 intronic C 42 43.7 275 33.4 1.55(1.01-2.38) 0.04
T 54 56.3 549 66.6
rs4665143 synonymous A 43 42.2 308 37.1 1.24(0.81-1.88) 0.32
G 59 57.8 522 62.9
rs877635 intronic A 52 49.1 199 23.9 3.07(2.03-4.64) 3.33E-08
C 54 50.9 635 76.1
rs2715928 intronic A 66 67.3 390 49.4 2.12(1.36-3.3) 7.83E-04
G 32 32.7 400 50.6
rs16844715 intronic C 75 72.1 378 45.3 3.12(1.99-4.89) 2.53E-07
T 29 27.9 456 54.7
rs3749119 5' UTR C 86 84.3 476 57.2 4.02(2.32-6.97) 1.31E-07
T 16 15.7 356 42.8
aOR: Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
bP-values for allele frequency comparisons between cases and controls using the chi-square test. 
SNP OR (95% CI)a P-valueb
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Table 3. Haplotype association analysis of PLA2R1 SNPs in the combined sample set
Haplotype Effect rs35771982 rs2715928 rs16844715 Case freq (n=183)
Control freq 
(n=805) OR (95% CI) P-value
H1 Risk G A C 0.573 0.368 2.31 (1.82; 2.94 ) 7.30E-13
H2 Protective C G T 0.191 0.406 0.34 (0.26; 0.45 ) 1.84E-14
H4 Neutral G G C 0.106 0.076 _ 0.06
H5 Neutral G A T 0.121 0.121 _ 1.00  
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Table 4. Association analysis of HLA-A alleles with IMN in the first set
HLA-A
allelesa
No % No %
A*01:01 0 0.0 10 1.2 0.37(0.02-6.38) 0.30 4.85
A*02:01 17 16.0 85 10.1 1.70(0.96-2.99) 0.06 1.03
A*02:06 8 7.5 61 7.3 1.04(0.48-2.24) 0.15 2.46
A*02:07 3 2.8 23 2.7 1.03(0.31-3.51) 0.24 3.86
A*11:01 11 10.4 80 9.5 1.10(0.57-2.14) 0.78 12.46
A*24:02 36 34.0 316 37.7 0.85(0.56-1.31) 0.46 7.41
A*24:20 0 0.0 10 1.2 0.37(0.02-6.38) 0.30 4.85
A*26:01 7 6.6 67 8.0 0.82(0.36-1.83) 0.14 2.28
A*26:02 3 2.8 12 1.4 2.01(0.56-7.24) 0.15 2.47
A*26:03 5 4.7 22 2.6 1.84(0.68-4.97) 0.10 1.67
A*31:01 12 11.3 67 8.0 1.47(0.77-2.82) 0.24 3.85
A*33:03 4 3.8 76 9.1 0.39(0.14-1.10) 0.03 0.42
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
PcOR (95% CI)b P-valuec
Allele frequency
IMN (2n=106) Control (2n=838)
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Table 5. Association analysis of HLA-B alleles with IMN in the first set
HLA-B
allelesa
No % No %
B*07:02 1 0.9 57 6.8 0.13(0.02-0.95) 6.33E-03 0.11
B*13:01 2 1.9 13 1.6 1.22(0.27-5.50) 0.28 5.11
B*15:01 15 14.2 71 8.5 1.79(0.98-3.25) 0.05 0.98
B*15:18 4 3.8 14 1.7 2.31(0.75-7.16) 0.09 1.64
B*35:01 15 14.2 67 8.0 1.90(1.04-3.47) 0.03 0.60
B*39:01 3 2.8 34 4.1 0.69(0.21-2.29) 0.19 3.49
B*40:01 5 4.7 46 5.5 0.85(0.33-2.20) 0.18 3.22
B*40:02 12 11.3 57 6.8 1.75(0.91-3.39) 0.09 1.63
B*40:06 4 3.8 34 4.1 0.93(0.32-2.67) 0.21 3.75
B*44:03 3 2.8 68 8.1 0.33(0.10-1.07) 0.02 0.40
B*46:01 4 3.8 38 4.5 0.83(0.29-2.37) 0.20 3.53
B*48:01 3 2.8 22 2.6 1.08(0.32-3.68) 0.24 4.32
B*51:01 8 7.5 71 8.5 0.88(0.41-1.89) 0.15 2.62
B*52:01 12 11.3 80 9.5 1.21(0.64-2.31) 0.56 10.01
B*54:01 5 4.7 65 7.8 0.59(0.23-1.50) 0.09 1.67
B*55:02 0 0.0 20 2.4 0.19(0.01-3.13) 0.09 1.63
B*59:01 1 0.9 16 1.9 0.49(0.06-3.74) 0.28 5.13
B*67:01 3 2.8 11 1.3 2.20(0.60-8.00) 0.14 2.50
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
Allele frequency
Pc
IMN (2n=106) Control (2n=838)
OR (95% CI)b P-valuec
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Table 6. Association analysis of HLA-C alleles with IMN in the first set
HLA-C
allelesa
No % No %
Cw*01:02 9 8.5 139 16.6 0.47(0.23-0.95) 0.01 0.12
Cw*03:03 22 20.8 113 13.5 1.68(1.01-2.80) 0.04 0.51
Cw*03:04 16 15.1 105 12.5 1.24(0.70-2.20) 0.45 5.41
Cw*04:01 6 5.7 42 5.0 1.14(0.47-2.75) 0.17 2.03
Cw*07:02 10 9.4 121 14.4 0.62(0.31-1.22) 0.16 1.95
Cw*07:04 5 4.7 7 0.8 5.89(1.84-18.91) 5.79E-03 0.07
Cw*08:01 8 7.5 48 5.7 1.35(0.62-2.93) 0.12 1.44
Cw*08:03 3 2.8 12 1.4 2.01(0.56-7.24) 0.15 1.85
Cw*12:02 12 11.3 81 9.7 1.20(0.63-2.28) 0.58 7.01
Cw*14:02 5 4.7 50 6.0 0.78(0.30-2.01) 0.16 1.97
Cw*14:03 3 2.8 69 8.2 0.33(0.10-1.05) 0.02 0.24
Cw*15:02 5 4.7 31 3.7 1.29(0.49-3.40) 0.17 2.04
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
OR (95% CI)b P-valuec
Allele frequency
IMN (2n=106) Control (2n=838)
Pc
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Table 7. Association analysis of HLA-DRB1 alleles with IMN in the first set
HLA-DRB1
allelesa
No % No %
DRB1*01:01 2 1.9 57 6.8 0.26(0.06-1.10) 0.02 0.46
DRB1*04:01 3 2.8 10 1.2 2.42(0.65-8.93) 0.12 2.58
DRB1*04:03 2 1.9 24 2.9 0.65(0.15-2.81) 0.24 4.97
DRB1*04:05 7 6.6 122 14.6 0.42(0.19-0.92) 0.01 0.18
DRB1*04:06 5 4.7 28 3.3 1.44(0.54-3.80) 0.15 3.20
DRB1*04:10 1 0.9 12 1.4 0.66(0.08-5.11) 0.35 7.38
DRB1*08:02 5 4.7 32 3.8 1.25(0.48-3.28) 0.18 3.68
DRB1*08:03 6 5.7 63 7.5 0.74(0.31-1.75) 0.13 2.83
DRB1*09:01 13 12.3 128 15.3 0.78(0.42-1.43) 0.42 8.77
DRB1*11:01 6 5.7 23 2.7 2.13(0.85-5.36) 0.06 1.27
DRB1*12:01 2 1.9 30 3.6 0.52(0.12-2.20) 0.18 3.69
DRB1*12:02 1 0.9 18 2.1 0.43(0.06-3.29) 0.25 5.26
DRB1*13:01 2 1.9 6 0.7 2.67(0.53-13.42) 0.17 3.63
DRB1*13:02 3 2.8 65 7.8 0.35(0.11-1.13) 0.03 0.59
DRB1*14:03 0 0.0 11 1.3 0.34(0.02-5.79) 0.27 5.64
DRB1*14:05 2 1.9 17 2.0 0.93(0.21-4.09) 0.29 6.04
DRB1*14:06 3 2.8 13 1.6 1.85(0.52-6.61) 0.17 3.55
DRB1*14:54 6 5.7 26 3.1 1.88(0.75-4.67) 0.08 1.71
DRB1*15:01 21 19.8 67 8.0 2.85(1.66-4.89) 7.72E-05 1.62E-03
DRB1*15:02 11 10.4 70 8.4 1.27(0.65-2.49) 0.48 10.05
DRB1*16:02 3 2.8 2 0.2 12.2(2.02-73.9) 0.01 0.23
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
Allele frequency
IMN (2n=106) Control (2n=838)
PcP-valuecOR (95% CI)b
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Table 8. Association analysis of HLA-DQB1 alleles with IMN in the first set
HLA-DQB1
allelesa
No % No %
DQB1*03:01 17 16.0 99 11.8 1.43(0.82-2.50) 0.21 2.50
DQB1*03:02 12 11.3 77 9.2 1.26(0.66-2.41) 0.47 5.69
DQB1*03:03 13 12.3 134 16.0 0.74(0.40-1.35) 0.32 3.88
DQB1*04:01 7 6.6 122 14.6 0.42(0.19-0.92) 0.01 0.10
DQB1*04:02 1 0.9 26 3.1 0.30(0.04-2.22) 0.14 1.63
DQB1*05:01 3 2.8 63 7.5 0.36(0.11-1.16) 0.03 0.39
DQB1*05:02 5 4.7 17 2.0 2.40(0.87-6.64) 0.06 0.73
DQB1*05:03 7 6.6 30 3.6 1.91(0.82-4.46) 0.06 0.77
DQB1*06:01 17 16.0 133 15.9 1.02(0.59-1.76) 0.96 11.48
DQB1*06:02 19 17.9 65 7.8 2.60(1.49-4.55) 5.12E-04 6.15E-03
DQB1*06:03 2 1.9 6 0.7 2.67(0.53-13.42) 0.17 2.07
DQB1*06:04 3 2.8 63 7.5 0.36(0.11-1.16) 0.03 0.39
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
Allele frequency
IMN (2n=106) Control (2n=838)
PcP-valuecOR (95% CI)b
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Table 9. Association analysis of HLA-DPB1 alleles with IMN in the first set
HLA-DPB1
allelesa
No % No %
DPB1*02:01 26 24.5 211 25.2 0.97(0.61-1.55) 0.89 9.84
DPB1*02:02 2 1.9 35 4.2 0.44(0.10-1.87) 0.13 1.42
DPB1*03:01 6 5.7 36 4.3 1.34(0.55-3.26) 0.15 1.61
DPB1*04:01 2 1.9 51 6.1 0.30(0.07-1.24) 0.04 0.41
DPB1*04:02 7 6.6 83 9.9 0.64(0.29-1.43) 0.08 0.93
DPB1*05:01 45 42.5 322 38.4 1.19(0.79-1.79) 0.41 4.53
DPB1*06:01 2 1.9 5 0.6 3.21(0.62-16.76) 0.15 1.60
DPB1*09:01 12 11.3 66 7.9 1.50(0.78-2.87) 0.22 2.44
DPB1*13:01 0 0.0 12 1.4 0.31(0.02-5.29) 0.24 2.62
DPB1*14:01 2 1.9 10 1.2 1.60(0.34-7.38) 0.25 2.80
DPB1*19:01 2 1.9 5 0.6 3.21(0.62-16.76) 0.15 1.60
aalleles: risk alleles with frequencies of less than 1% in both cases and controls are omitted.
bOR  : Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
cP-values for allele frequency comparisons between cases and controls using the chi-square test. 
Pc: Corrected P-value for the number of alleles tested.
Pc
Allele frequency
IMN (2n=106) Control (2n=838)
OR (95% CI)b P-valuec
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Table 12. Frequency disribution of DRB1-DQB1haplotypes in Japanese IMN patients and controls
No % No %
DRB1*01:01-DQB1*05:01 13 7.1% 115 14.4% 0.48(0.27-0.86) 0.01
DRB1*04:01-DQB1*03:01 12 6.6% 20 2.5% 2.71(1.31-5.59) 5.16E-03
DRB1*04:03-DQB1*03:02 6 3.3% 46 5.8% 0.57(0.24-1.34) 0.07
DRB1*04:05-DQB1*04:01 30 16.5% 194 24.3% 0.65(0.44-0.98) 0.04
DRB1*04:06-DQB1*03:02 14 7.7% 61 7.6% 1.01(0.56-1.83) 0.96
DRB1*04:10-DQB1*04:02 2 1.1% 21 2.6% 0.42(0.1-1.79) 0.12
DRB1*08:02-DQB1*03:02 7 3.8% 33 4.1% 0.94(0.41-2.13) 0.16
DRB1*08:02-DQB1*04:02 5 2.7% 28 3.5% 0.79(0.3-2.05) 0.17
DRB1*08:03-DQB1*06:01 18 9.9% 124 15.5% 0.62(0.37-1.03) 0.06
DRB1*09:01 DQB1*03:03 35 19.2% 222 27.8% 0.66(0.46-0.97) 0.03
DRB1*10:01 DQB1*05:01 1 0.5% 8 1.0% 0.55(0.07-4.42) 0.32
DRB1*11:01 DQB1*03:01 18 9.9% 35 4.4% 2.34(1.31-4.17) 3.21E-03
DRB1*12:01 DQB1*03:01 7 3.8% 37 4.6% 0.83(0.37-1.88) 0.15
DRB1*12:01 DQB1*03:03 4 2.2% 10 1.3% 1.77(0.55-5.69) 0.15
DRB1*12:02 DQB1*03:01 3 1.6% 27 3.4% 0.49(0.15-1.61) 0.10
DRB1*13:01 DQB1*06:03 3 1.6% 8 1.0% 1.66(0.44-6.29) 0.20
DRB1*13:02 DQB1*06:04 12 6.6% 116 14.5% 0.44(0.24-0.8) 6.10E-03
DRB1*13:02 DQB1*06:09 0 0.0% 11 1.4% 0.19(0.01-3.24) 0.11
DRB1*14:03 DQB1*03:01 4 2.2% 27 3.4% 0.65(0.23-1.87) 0.15
DRB1*14:05 DQB1*05:03 11 6.0% 29 3.6% 1.7(0.84-3.43) 0.14
DRB1*14:06 DQB1*03:01 9 4.9% 25 3.1% 1.6(0.74-3.47) 0.08
DRB1*14:54 DQB1*05:02 11 6.0% 16 2.0% 3.1(1.43-6.73) 2.67E-03
DRB1*14:54 DQB1*05:03 11 6.0% 32 4.0% 1.53(0.77-3.07) 0.22
DRB1*15:01 DQB1*03:01 4 2.2% 2 0.3% 8.92(1.63-48.87) 0.01
DRB1*15:01 DQB1*06:02 69 37.9% 114 14.3% 3.07(2.22-4.24) 1.89E-12
DRB1*15:02 DQB1*06:01 42 23.1% 172 21.5% 1.09(0.76-1.56) 0.64
DRB1*16:02 DQB1*05:02 5 2.7% 9 1.1% 2.47(0.82-7.42) 0.07
aOR: Odds ratio; 95% CI: lower and upper limits of confidence interval at 95%.
bP-value for allele or genotype frequency comparisons between cases and controls using the chi-square test. 
Haplotypes with frequencies of < 1% in both cases and controls are omitted.
DRB1-DQB1 haplotypes IMN (n=182) Control (n=799) OR (95% CI)a P-valueb
!
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Table 13. Interaction analysis between HLA-DRB1*15:01-DQB1*06:02 haplotype and PLA2R1 risk variants
No % No %
DRB1*15:01-DQB1*06:02 rs1511223: A/A
+ + 45 25.4 44 5.5 9(5.32-15.24) 1.25E-19 5.68
+ - 17 9.6 65 8.2 2.3(1.23-4.3) 7.44E-03
- + 74 41.8 323 40.7 2.02(1.34-3.04) 6.78E-04
- - 41 23.2 361 45.5 1
DRB1*15:01-DQB1*06:02 rs35771982: G/G
+ + 41 23.2 27 3.4 15.91(8.94-28.3) 2.76E-29 10.88
+ - 21 11.9 82 10.4 2.68(1.52-4.75) 4.74E-04
- + 71 40.1 222 28.0 3.35(2.23-5.04) 1.78E-09
- - 44 24.9 461 58.2 1
DRB1*15:01-DQB1*06:02 rs2715928: A/A
+ + 33 18.6 15 1.9 17.53(9.03-34.03) 4.26E-26 13.72
+ - 29 16.4 94 11.9 2.46(1.5-4.02) 2.35E-04
- + 51 28.8 173 21.8 2.35(1.56-3.53) 2.68E-05
- - 64 36.2 510 64.4 1
DRB1*15:01-DQB1*06:02 rs16844715: C/C
+ + 34 19.2 18 2.3 15.91(8.49-29.79) 2.30E-26 11.34
+ - 28 15.8 91 11.5 2.59(1.58-4.26) 1.13E-04
- + 51 28.8 144 18.2 2.98(1.98-4.5) 1.98E-07
- - 64 36.2 539 68.1 1
DRB1*15:01-DQB1*06:02 rs3749119: C/C
+ + 41 23.2 27 3.4 15.86(8.9-28.26) 6.42E-29 10.98
+ - 21 11.9 82 10.4 2.67(1.51-4.74) 5.21E-04
- + 72 40.7 234 29.5 3.21(2.13-4.84) 7.29E-09
- - 43 24.3 449 56.7 1
RERI: Relative Excess Risk due to Interaction.
RERIHLA PLA2R1 IMN (N=182) Controls (N=799) OR (95%CI) P-value
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PART%I:%Fine%mapping%study%of%PLA2R1'
419%healthy%control%individuals%(from%
University%of%Tokyo)%
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(from%University%of%Tokyo%Hospital%and%
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Stage&Three:&Combined&data&analysis&
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SelecKon%of%signiﬁcant%SNPs%
130%biopsyJproven%IMN%paKents%
%(from%RIKEN,%Japan)%
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%%%%%%(TaqMan%SNP%genotyping%assay)%
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183%IMN%paKents%
(from%stage%one%and%two)%
%CaseJcontrol%associaKon%
J%Single%point%analysis%
J%Haplotype%associaKon%test%
Figure 1. Schematic presentation of overflow of fine mapping study of PLA2R1 in Japanese IMN patients 
and controls 
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Figure 2: Location of tag SNPs at PLA2R1 locus. LD block images with approximate locations of 
the 12 SNP markers selected in this study, recombination spots and LD patterns within JPT LD plot 
of the PLA2R1 gene. 
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PART%II:%HLA%study$
419%healthy%control%individuals%(from%
University%of%Tokyo)%
Stage&One:&Discovery&study&
•  HLA%typing%of$HLA'A,%B,%C,%DRB1,%DQB1,%DPB1$
•  CaseDcontrol%associaEon%(Single%point%analysis)%
Stage&Two:&Replica9on&study&&
392%healthy%control%individuals%
(from%University%of%Tokyo%Hospital%and%
PharmaSNP%ConsorEum)%
811%healthy%control%individuals%
(from%stage%one%and%two)%
Stage&Three:&Combined&data&analysis&
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University%of%Tokyo%Hospital)%%%
SelecEon%of%signiﬁcant%HLA%alleles%(DRB1,%DQB1)%
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%(from%RIKEN,%Japan)%
•  HLA%typing%of%HLA'DRB1$and%DQB1$
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%CaseDcontrol%associaEon%
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Figure 3. Schematic presentation of overflow of HLA study of Japanese IMN patients and controls 
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Figure 4. Schematic presentation of overview process in HLA typing using WAKFlow HLA typing kit 
 (Figure modified from http://www.wakunagahla.jp/english/products/wakflow/index.html) 
 
